Table 1.
Patients, disease and treatment characteristics.
| No. | % (n = 441) | |
|---|---|---|
| Median age of diagnosis, years (range) | 60 (18–85) | |
| Sex | ||
| Female | 145 | 32.9 |
| Male | 296 | 67.1 |
| Location of primary tumor | ||
| Gastroesophageal junction | 204 | 46.3 |
| Corpus | 116 | 26.3 |
| Antrum | 106 | 24 |
| Fundus | 15 | 3.4 |
| ECOG Performance Score | ||
| 0–1 | 398 | 90.2 |
| 2 | 11 | 2.5 |
| Unknown | 32 | 7.3 |
| cT-N stage | 338 | |
| T1/T2 N (−) | 3 | 0.9 |
| T1/T2 N (+) | 16 | 4.7 |
| T3/T4 N (−) | 15 | 4.4 |
| T3/T4 N (+) | 304 | 89.9 |
| Signet cells | ||
| Yes | 124 | 28.1 |
| No | 218 | 40.4 |
| Missing | 99 | 22.5 |
| Grade | ||
| Grade 1 | 32 | 7.2 |
| Grade 2 | 137 | 31.1 |
| Grade 3 | 169 | 38.3 |
| Undifferentiated | 18 | 4.1 |
| Missing | 85 | 19.3 |
| HER2 status | 262 | |
| Positive | 15 | 5.7 |
| Negative | 247 | 94.3 |
| The median cycle of neoadjuvant FLOT, range | 4 (1–12) | |
| The median cycle of adjuvant chemotherapy, range | 4 (0–8) | |
| FLOT | 298 | 89 |
| 5-FU and -platin | 16 | 4.8 |
| 5-FU | 6 | 1.8 |
| Others | 15 | 4.4 |
| Adjuvant radiotherapy | ||
| Yes | 75 | 17 |
| No | 366 | 83 |
| Surgery | ||
| Yes | 413 | 93.7 |
| No | 28 | 6.3 |
| Pretreatment median hemoglobine, gr/dL, IQR | 12 (10.6–13.7) | |
| Pretreatment median NLR, IQR | 2.8 (1.96–3.90) | |
| ≥2.8 | 116 | 50 |
| Pretreatment median PLR, IQR | 167.7 (119.2–236.3) | |
| ≥167.7 | 117 | 50.4 |
| Pretreatment median CEA, ng/mL, IQR | 2.6 (1.18–8.43) | |
| Pretreatment median CA19-9, U/mL, IQR | 15.5 (6.4–54) | |
| Pretreatment median albumin, mg/dL, IQR | 3.9 (3.6–4.2) | |
| <3 | 8 | 3.5 |